News | News By Subject | News by Disease News By Date | Search News

Thrombocytopenia News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Geron Corporation (GERN) Tanks As FDA Halts Development Of Blood Disorder Drug     3/13/2014
CytoPharm and Amarillo Biosciences (AMAR) Announce Positive HCV Study Results: Oral Interferon Found to Reverse Thrombocytopenia; Reduced Relapse Rate Seen in Patients With Mild Fibrosis     6/15/2012
Exelixis, Inc. (EXEL) Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients With Hepatocellular Carcinoma     1/23/2012
Amgen (AMGN)'s Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints     12/10/2007
MGI PHARMA, INC. (MOGN) Buys Rights To AkaRx, Inc.'s Blood-Cell Disorder Drug: Upfront Payments of Up to $45 Million     8/29/2007
FDA Approves CSL Behring's Rhophylac(R) for the Treatment of Immune Thrombocytopenic Purpura (ITP)     4/2/2007
Baxter Healthcare Corporation (BAX) Assumes Marketing And Distribution Rights For Cangene Corporation's WinRho SDF In The U.S.     3/29/2005
Alexion Pharmaceuticals (ALXN) And XOMA (XOMA) Form Collaboration     12/18/2003
Puget Sound Blood Center Release: Gene That May Provide Link To Bleeding Disorders Discovered     12/2/2003

News from Around the Web

Press Releases
CTI BioPharma Announces EMA Validation Of Pacritinib Marketing Authorization Application For Patients With Myelofibrosis Who Have Thrombocytopenia     7/14/2017
FDA Accepts Rigel (RIGL)'s New Drug Application For TAVALISSE (Fostamatinib Disodium) For The Treatment Of Chronic ITP     6/19/2017
Rigel (RIGL) Submits New Drug Application To FDA For Fostamatinib In Chronic ITP     4/18/2017
Shire (SHPG) Receives FDA Fast Track Designation For Recombinant ADAMTS13 (SHP655) For Treatment Of Hereditary Thrombotic Thrombocytopenic Purpura     3/22/2017
FDA Approves Bio Products Laboratory's Gammaplex 10% For Treatment Of Primary Immunodeficiency And Chronic Immune Thrombocytopenic Purpura     2/7/2017
Rigel (RIGL) Release: Fostamatinib Study Results Continue To Trend Positive     1/30/2017
Galena Biopharma  (GALE) Stocks Jump After FDA Meeting, Blood Cancer Therapy GALE-401 to Enter Phase III     12/28/2016
CTI BioPharma Release: PERSIST-2 Phase 3 Study Of Pacritinib Versus Best Available Therapy Shows Encouraging Clinical Activity In High-Risk Patients With Advanced Myelofibrosis In Late-Breaking Session At American Society of Hematology Annual Meeting     12/6/2016
Baxalta (BXLT) Reports Positive Phase 1 Results For BAX 930, Investigational Recombinant ADAMTS13 To Treat Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)     5/25/2016
Xencor Reports Complete Data Results From XmAb7195 Phase 1a Trial Showing Rapid Reduction Of Serum IgE In High IgE Atopic Subjects At American Thoracic Society 2016 International Conference     5/19/2016
Protalex, Inc. (PRTX) Receives Positive Interim Review From Independent Safety Monitoring Committee In Its European Phase Ib Study Of PRTX-100 To Treat Immune Thrombocytopenia     5/2/2016
Amgen (AMGN) Release: Nplate (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia     4/20/2016
New Patent Issued To Cantex Pharmaceuticals For Its Lead Product Candidate In The Treatment Of Thrombocytopenia And Neutropenia     3/2/2016
Protalex, Inc. (PRTX) Receives Positive Interim Review From Independent Safety Monitoring Committee In Its U.S. Phase I/II Study Of PRTX-100 For Immune Thrombocytopenia     2/29/2016
DelMar Pharma To Present At The Biotech Showcase 2016 On January 12, 2016     1/5/2016